• Belite Bio posted a GAAP net loss of USD 26.94 million for the quarter ended March 31, 2026, widening from USD 14.28 million a year earlier.
• Research and development expense climbed to USD 15.66 million from USD 9.4 million, due to higher DRAGON II trial costs, API and drug product manufacturing, consultant fees.
• Selling, general and administrative expense rose to USD 17.02 million from USD 6.12 million, on higher share-based compensation, professional fees, wages and salaries tied to team expansion.
• Other income increased to USD 5.75 million from USD 1.24 million, driven by interest income from bank deposits, U.S. treasury bills and U.S. treasury notes.
• Initiated a rolling NDA submission to the FDA in April for tinlarebant in Stargardt disease type 1, expected to be completed in the second quarter of 2026, with cash and cash equivalents plus U.S. treasury bills and notes totaling USD 798.6 million at March 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605200600PRIMZONEFULLFEED9723728) on May 20, 2026, and is solely responsible for the information contained therein.